Table of contents

December 2022 - Volume 93 - 12

Editorial commentary

Neuromuscular

Neurodegeneration

Neurogenetics

Epilepsy

Multiple sclerosis

  • Original research: Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis (30 September, 2022)
    Doriana Landi, Francesca Bovis, Alfonso Grimaldi, Pietro Osvaldo Annovazzi, Antonio Bertolotto, Alessia Bianchi, Giovanna Borriello, Vincenzo Brescia Morra, Sebastiano Bucello, Maria Chiara Buscarinu, Francesca Caleri, Marco Capobianco, Ruggero Capra, Maria Cellerino, Diego Centonze, Raffaella Cerqua, Clara Grazia Chisari, Marinella Clerico, Eleonora Cocco, Gaia Cola, Cinzia Cordioli, Erica Curti, Alessandro d'Ambrosio, Emanuele D'Amico, Giovanna De Luca, Massimiliano Di Filippo, Sonia Di Lemme, Roberta Fantozzi, Diana Ferraro, Elisabetta Ferraro, Antonio Gallo, Claudio Gasperini, Franco Granella, Matilde Inglese, Roberta Lanzillo, Lorena Lorefice, Giacomo Lus, Simona Malucchi, Monica Margoni, Giorgia Mataluni, Massimiliano Mirabella, Lucia Moiola, Carolina Gabri Nicoletti, Viviana Nociti, Francesco Patti, Federica Pinardi, Emilio Portaccio, Carlo Pozzilli, Paolo Ragonese, Sarah Rasia, Giuseppe Salemi, Elisabetta Signoriello, Francesca Vitetta, Rocco Totaro, Maria Pia Sormani, Maria Pia Amato, Girolama Alessandra Marfia
  • Original research: Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark (28 September, 2022)
    Elisabeth Framke, Luigi Pontieri, Stephan Bramow, Finn Sellebjerg, Melinda Magyari
  • Original research: Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry (30 September, 2022)
    Sifat Sharmin, Charles B Malpas, Izanne Roos, Ibrahima Diouf, Raed Alroughani, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Dana Horakova, Eva K Havrdova, Francesco Patti, Murat Terzi, Cavit Boz, Bassem Yamout, Samia J Khoury, Marco Onofrj, Alessandra Lugaresi, Ayse Altintas, Alexandre Prat, Marc Girard, Pierre Duquette, Maria José , Daniele La Spitaleri, Youssef Sidhom, Riadh Gouider, Saloua Mrabet, Aysun Soysal, Recai Turkoglu, Maria Pia Amato, Yara D Fragoso, Tomas Kalincik
  • Original research: Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis (19 October, 2022)
    Chao Zhu, Zhen Zhou, Izanne Roos, Daniel Merlo, Tomas Kalincik, Serkan Ozakbas,, Olga Skibina, Jens Kuhle, Suzanne Hodgkinson, Cavit Boz, Raed Alroughani, Jeannette Lechner-Scott, Michael Barnett, Guillermo Izquierdo, Alexandre Prat, Dana Horakova, Eva Kubala Havrdova, Richard Macdonell, Francesco Patti, Samia Joseph Khoury, Mark Slee, Rana Karabudak, Marco Onofrj, Vincent Van Pesch, Julie Prevost, Mastura Monif, Vilija Jokubaitis, Anneke van der Walt, Helmut Butzkueven

Movement disorders

Neuro-inflammation

Electronic page